Manage Medication GLP-1 Weight Loss Series Feeling Stuck
You can also view the full study including codes, definitions, and more directly in Truveta Studio
Bogen er henvendt til de forskningsinteresserede og de, der nsker at forst GLP-1-forskningen i dybden
Retatrutide shows potential for greater efficacy through triple-agonism but awaits Phase 3 results Best For Recommendations# Currently Available Treatment# Recommendation : Tirzepatide Reason : FDA-approved and commercially available as Mounjaro/Zepbound with established dosing protocols and post-market safety data Maximum Weight Loss Potential# Recommendation : Retatrutide Reason : Phase 2 data showed 24.2% weight loss at 48 weeks, exceeding tirzepatide's results, though Phase 3 confirmation is pending Non-Alcoholic Fatty Liver Disease# Recommendation : Retatrutide Reason : Glucagon receptor agonism directly promotes hepatic fat oxidation, showing up to 82% liver fat reduction in trials Type 2 Diabetes Management# Recommendation : Tirzepatide Reason : Proven HbA1c reduction with FDA approval specifically for glycemic control in type 2 diabetes Further Reading# Which Is Better For
If the family history is papillary, follicular, or Oncocytic (Hrthle cell) cancer, this is not a contraindication
Lancet Diabetes Endocrinol 2021;9:743-54.ArticlePubMed 59
